摘要
Abstract
Objective:To investigate the therapeutic effect of camrelizumab combined with sorafenib in patients with advanced unresectable hepatocellular carcinoma.Methods:Medical records of 65 patients with advanced unresectable hepatocellular carcinoma admitted to the oncology department of a hospital from December 2020 to December 2023 were retrospectively collected.They were divided into the control group(n=30)and the observation group(n=35)according to different treatment regimens.All patients underwent transcatheter arterial chemoembolization(TACE).The control group was treated with sorafenib tosylate tablets,while the observation group was treated with camrelizumab for injection combined with sorafenib tosylate tablets.Clinical efficacy,tumor markers[alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA)],immune function indicators(CD3+,CD4+,CD8+,CD4+/CD8+),angiogenic factors[vascular endothelial growth factor(VEGF),platelet-derived growth factor(PDGF)],adverse reactions and survival status were compared between the two groups.Results:After treatment,the disease control rate in the observation group(91.43%)was higher than that in the control group(70.00%,P<0.05).Levels of AFP,CEA,VEGF and PDGF were decreased in both groups,with lower levels in the observation group(P<0.05).CD3+,CD4+and CD4+/CD8+were decreased in both groups,but the observation group showed higher levels(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).After 12 months of follow-up,progression-free survival(PFS)and overall survival(OS)in the observation group were longer than those in the control group(P<0.05),while there was no statistically significant difference in 1-year survival rate(P>0.05).Conclusion:Camrelizumab combined with sorafenib can improve clinical efficacy in patients with advanced unresectable hepatocellular carcinoma,reduce tumor marker levels,exert immune protection and anti-angiogenic effects,prolong overall survival,and does not increase the risk of adverse reactions.关键词
肝细胞癌/晚期/不可切除/卡瑞利珠单抗/索拉非尼/免疫/安全性Key words
hepatocellular carcinoma/advanced/unresectable/carilizumab/sorafenib/immunity/safety分类
医药卫生
